scholarly journals İLERİ EVRE/REKÜREN OVER KANSERİ NEDENİYLE HİPERTERMİK İNTRAPERİTONYAL KEMOTERAPİ (HIPEC) UYGULADIĞIMIZ HASTALARDAKİ PEROPERATİF TECRÜBEMİZ Our peroperative experience in patients who underwent Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced stage/recurrent ovarian cancer

2019 ◽  
Author(s):  
Oğuzhan Kuru ◽  
Mehmet Gökçü
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Recurrent Ovarian Cancer ◽  
Advanced Stage

scholarly journals Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Diagnostics ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. 43 ◽  
Author(s):  
McKayla J. Riggs ◽  
Prakash K. Pandalai ◽  
Joseph Kim ◽  
Charles S. Dietrich
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Residual Tumor ◽  
Recurrent Ovarian Cancer ◽  
Adjunctive Treatment ◽  
Intravenous Route ◽  
History Of ◽  
Systemic Side Effects ◽  
Chemotherapy Agents

Hyperthermic intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery (CRS) holds promise as an adjunctive treatment strategy in malignancies affecting the peritoneal surface, effectively targeting remaining microscopic residual tumor. HIPEC increases concentrations of chemotherapy directly within the peritoneal cavity compared with the intravenous route and reduces the systemic side effects associated with prolonged adjuvant intraperitoneal exposure. Furthermore, hyperthermia increases tissue penetration and is synergistic with the therapeutic chemotherapy agents used. In ovarian cancer, evidence is building for its use in both primary and recurrent scenarios. In this review, we examine the history of HIPEC, the techniques used, and the available data guiding its use in primary and recurrent ovarian cancer.

Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al

2017 ◽  
Vol 27 (2) ◽  
pp. 246-247 ◽  
Author(s):  
Philipp Harter ◽  
Alexander Reuss ◽  
Jalid Sehouli ◽  
Luis Chiva ◽  
Andreas du Bois
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Recurrent Ovarian Cancer ◽  
Phase 3

AbstractA published so-called phase 3 study regarding HIPEC in ovarian cancer raised multiple questions. This commentary focusses on the weakness of the publication and discusses this in detail.

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update

2020 ◽  
Vol 41 (3) ◽  
Author(s):  
Aurélie Revaux ◽  
Marie Carbonnel ◽  
Frédéric Kanso ◽  
Iptissem Naoura ◽  
Jennifer Asmar ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Delivery ◽  
Clinical Trials ◽  
Intraperitoneal Chemotherapy ◽  
Clinical Studies ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Late Recurrence ◽  
Advanced Stage ◽  
Major Objective ◽  
Interesting Approach

AbstractIn the treatment of advanced-stage epithelial ovarian cancer (EOC)-associated surgery and chemotherapy with intravenous platinum/taxane-based therapy most patients had early or late recurrence. Prevention of progression and recurrence is a major objective for the management of EOC. Recently, many clinical studies have evaluated the strategy with hyperthermic intraoperative intraperitoneal (IP) drug delivery. This is an update of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in EOC and a view for future strategies. Until recently studies on HIPEC in patients with EOC were mostly retrospective and heterogeneous. Thanks to recent clinical trials, it is reasonable to conclude that surgical cytoreduction and HIPEC is an interesting approach in the management of EOC without increasing morbidity.

Sign in / Sign up

Export Citation Format

Share Document